Sen. Baucus “Expects Answers” On Sen. Grassley’s FDA Inquiries
Executive Summary
The inquiries by Senate Finance Committee Ranking Minority Member Chuck Grassley, R-Iowa, into FDA carry the imprimatur of committee chairman Max Baucus, D-Mont., even though the two senators traded leadership positions with the start of the 110 Congress, Baucus says
You may also be interested in...
Ketek Is Emerging As Lens For Wider Hill Scrutiny Of Clinical Trial Integrity
The House Energy and Commerce Committee's inquiries into Sanofi-Aventis' Ketek could be a jumping-off point for a wide-ranging congressional look into the integrity of clinical trials and oversight of companies involved in those trials
Profile Of A Drug Safety Scandal: Avandia Appears Headed Down Familiar Path
With FDA planning an advisory committee review and Congress calling for hearings, the detection of a cardiovascular safety signal for GlaxoSmithKline's type 2 diabetes therapy Avandia has all the hallmarks of a classic drug safety scandal
Profile Of A Drug Safety Scandal: Avandia Appears Headed Down Familiar Path
With FDA planning an advisory committee review and Congress calling for hearings, the detection of a cardiovascular safety signal for GlaxoSmithKline's type 2 diabetes therapy Avandia has all the hallmarks of a classic drug safety scandal